CD20/Firefly Luciferase CHO Cell Line | 78620

CD20/Firefly Luciferase CHO Cell Line | 78620 | Gentaur US, UK & Europe Disrtribition

Category: CAR-T/Cell Line

Application: Useful for CD20 binding assays to screen for potential CD20 ligands. Useful as CD20-expressing target cells in co-culture assays with Anti-CD20-CAR-T cells.

Background: CD20 (MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. CD20 is a highly attractive target antigen for immunotherapy because it is highly expressed in more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an "Essential Medicine". Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin's lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse.

Description: Recombinant clonal stable CHO-K1 cell line constitutively expressing both the full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866), and the firefly (Photinus pyralis) luciferase. Surface expression of CD20 was confirmed by flow cytometry.

Product Type: Cell Line

Shippement Condition: -80°C